SID Medicos Reaches 200 Lemon Bottle Academies in the UK
LONDON--(BUSINESS WIRE)-- SID Medicos, the South Korean cosmetics business developing advanced aesthetic solutions, has announced that the number of its Lemon Bottle Academies operating in the UK has reached 200.
The UK Academies form a major part of SID Medicos' global network of 330 Lemon Bottle Academies worldwide, which underscores the brand's commitment to advancing aesthetic practices globally.
Lemon Bottle Academies provides practitioners with CPD-accredited training on best practice for safely administering Lemon Bottle treatments to the highest standard. They offer specialised training programmes for skincare and fat-dissolving treatments, developed by independent, experienced practitioners to set a high standard in aesthetic practice.
Notably, most UK academies are led by female CEOs, creating opportunities for women to advance professionally, and demonstrating how the Lemon Bottle initiative goes beyond aesthetics to foster empowerment and leadership.
To ensure excellence, SID Medicos has established a clear pathway for aspiring academy owners:
Educational eligibility: Candidates must present a CPD badge confirming their qualification to offer fat-dissolving treatments in the UK.
Mastering the protocol: Completion of the Official Lemon Bottle Academy training to master the unique and safer Lemon Bottle protocols. 1 st generation academies are the original academies that were set up, providing specialist knowledge.
Course creation and certification: Candidates must develop a specific manual for the Lemon Bottle training program and obtain accreditation through SID Medicos-approved bodies, such as the CPD Group.
Over 1,500 individuals have enrolled in Lemon Bottle training courses globally, reflecting the high demand for these innovative solutions. This growing network of trained professionals ensures the consistent delivery of high-quality treatments worldwide.
Other practitioners can develop their knowledge, inspire others, and deliver exceptional results by enrolling in a Lemon Bottle course or starting their own academy.
Hong Sang Hyeon, Chief Executive Officer of SID Medicos, said: 'The continued growth of our network of Lemon Bottle Academies reflects the popularity of Lemon Bottle treatments among practitioners and patients. By training a new generation of practitioners, our academies are ensuring the highest standards of delivery for our treatments across the UK and globally, and providing opportunities for practitioners to advance their careers.'
About SID Medicos
SID Medicos is a South Korean company specialising in the distribution and supply of medical aesthetic products. It is the brand owner of Lemon Bottle, a Korean lipolysis and skin booster solution. Through continuous research and development in collaboration with plastic surgeons and dermatologists, SID Medicos aims to provide comprehensive aesthetic solutions. The company's commitment to high-quality products is evident in its strict manufacturing standards and the use of advanced technologies in the production processes.
Lemon Bottle carries the following region-specific cosmetic certifications:
1. CPNP : Europe
2. SCPN : UK
3. NMPA : China
4. PMDA : Japan
5. Health Canada : Canada
6. EAC : Russia
7. CCPN : Saudi Arabia
8. FDA MoCRA : USA
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
18 hours ago
- Yahoo
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEW YORK, June 06, 2025--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that the Compensation Committee of the Company's Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 39,345 shares of the Company's common stock to four new employees (the "Inducement Grants") on June 5, 2025 (the "Grant Date"). The Inducement Grants have been granted pursuant to the Company's 2025 Inducement Plan (the "Plan"). The Inducement Grants were granted as an inducement material to these individuals entering into employment with Neurogene in accordance with Nasdaq Listing Rule 5635(c)(4). The Inducement Grants have an exercise price per share that is equal to the closing price of Neurogene's common stock on the Grant Date. The Inducement Grants will vest over four years, with 25 percent vesting on the first anniversary of the vesting commencement date and thereafter in equal portions upon the lapse of each three-month period over the following 36-month period, subject to the employee's continued employment with Neurogene through the applicable vesting dates. About Neurogene The mission of Neurogene is to treat devastating neurological diseases to improve the lives of patients and families impacted by these rare diseases. Neurogene is developing novel approaches and treatments to address the limitations of conventional gene therapy in central nervous system disorders. This includes selecting a delivery approach to maximize distribution to target tissues and designing products to maximize potency and purity for an optimized efficacy and safety profile. The Company's novel and proprietary EXACT™ transgene regulation platform technology allows for the delivery of therapeutic levels while limiting transgene toxicity associated with conventional gene therapy. Neurogene has constructed a state-of-the-art gene therapy manufacturing facility in Houston, Texas. CGMP production of NGN-401 was conducted in this facility and will support pivotal clinical development activities. For more information, visit View source version on Contacts Company Contact: Cara MayfieldVice President, Corporate Investor Contact: Melissa ForstArgot PartnersNeurogene@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Boston Globe
18 hours ago
- Boston Globe
Bad Botox? Six cases of botulism on the South Shore tied to possible Botox injections
South Shore Health declined to answer questions about whether they were treating suspected cases or how many they were seeing, referring instead to the Department of Public Health. Advertisement However Jason Tracy, chief medical officer at the hospital, said generally that patients are given a presumptive diagnosis made off of their clinical presentation of symptoms and history of recent injections. Related : From there, the hospital would involve both the Department of Public Health and the Centers for Disease Control, which has an anti-toxin that it provides on a case-by-case basis. The anti-toxin helps slow the progression of symptoms, but does not reverse them, and so hospitals typically also provide supportive measures. 'This is quite rare,' Tracy said. 'This is different than a food-borne botulism type case. It's not as though there is a lot body of literature to refer clinicians to to give prognosis and historical elements and time courses for what to expect.' South Shore Hospital in Weymouth. Pat Greenhouse/Globe Staff Use of botulinum toxin — commonly known by the popular brand name Botox — for cosmetic procedures is widely Advertisement Cosmetic treatments with botulinum toxin use doses much lower than for medical treatments, said Dr. Mathew M. Avram, director of the Mass General Hospital Dermatology Laser and Cosmetic Center.. With regulated, FDA-approved products in a healthy adult, the amount of the toxin is so small that it is exceedingly rare for it to cause botulism. 'I've never seen a patient or had a colleague of mine at Mass General or elsewhere that has told me they have had a case of this. It is not something that happens normally,' Avram said. 'Someone would have to go outside the realm of what you would typically inject to encounter these issues, for a typical patient.' Beyond injecting far too much, poor administration technique or using counterfeit products can increase risks. 'We have seen instances where injectors have used counterfeit products or products they developed on their own,' Avram said. 'These are unsafe practices that can harm patients.' According to the advisory, botulism results when the botulinum toxin circulates in the blood. Symptoms including double or blurred vision, drooping eyelids, slurred speech, difficulty swallowing, and difficulty breathing. Such symptoms are sometimes followed by muscle weaknesses, which can progress over the course of hours or days. Advertisement DPH has asked clinicians to warn patients interested in these cosmetic injections of the potential risks, and is advising patients to receive injections only from licensed providers. 'If someone has had a botox injection and has had those symptoms they should seek medical attention,' Tracy said. 'I don't want to create worry but someone having visual changes, slurred speech and difficulty swallowing — they should not ignore it." The reports are only the latest Botox problems to surface in the South Shore. In November, 38-year-old Rebecca Fadanelli, was arrested and charged for selling counterfeit Botox out of Skin Beauté Med Spa in Easton and Randolph. Jessica Bartlett can be reached at
Yahoo
19 hours ago
- Yahoo
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEW YORK, June 06, 2025--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that the Compensation Committee of the Company's Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 39,345 shares of the Company's common stock to four new employees (the "Inducement Grants") on June 5, 2025 (the "Grant Date"). The Inducement Grants have been granted pursuant to the Company's 2025 Inducement Plan (the "Plan"). The Inducement Grants were granted as an inducement material to these individuals entering into employment with Neurogene in accordance with Nasdaq Listing Rule 5635(c)(4). The Inducement Grants have an exercise price per share that is equal to the closing price of Neurogene's common stock on the Grant Date. The Inducement Grants will vest over four years, with 25 percent vesting on the first anniversary of the vesting commencement date and thereafter in equal portions upon the lapse of each three-month period over the following 36-month period, subject to the employee's continued employment with Neurogene through the applicable vesting dates. About Neurogene The mission of Neurogene is to treat devastating neurological diseases to improve the lives of patients and families impacted by these rare diseases. Neurogene is developing novel approaches and treatments to address the limitations of conventional gene therapy in central nervous system disorders. This includes selecting a delivery approach to maximize distribution to target tissues and designing products to maximize potency and purity for an optimized efficacy and safety profile. The Company's novel and proprietary EXACT™ transgene regulation platform technology allows for the delivery of therapeutic levels while limiting transgene toxicity associated with conventional gene therapy. Neurogene has constructed a state-of-the-art gene therapy manufacturing facility in Houston, Texas. CGMP production of NGN-401 was conducted in this facility and will support pivotal clinical development activities. For more information, visit View source version on Contacts Company Contact: Cara MayfieldVice President, Corporate Investor Contact: Melissa ForstArgot PartnersNeurogene@
